Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Lab21 Partners with Top 10 IVD Player

Published: Wednesday, April 11, 2012
Last Updated: Wednesday, April 11, 2012
Bookmark and Share
Agreement to develop, manufacture and distribute new Aspergillus molecular assay.

Lab21 Limited has entered into an agreement with one of the world’s leading diagnostic businesses to develop, manufacture and distribute a diagnostic assay for the detection of Aspergillus species for the partner’s real time PCR platform.

Financial details of the agreement were not disclosed.

Under the agreement Lab21 will use its molecular diagnostic development resource and proprietary intellectual property in the fungal diagnostic area to develop and manufacture the new Aspergillus test as OEM reagents for the partner platform.

Graham Mullis, CEO of Lab21, commented: “We are pleased to enter into a new agreement to develop this assay. The MycAssay™ Aspergillus test provides rapid, accurate clinical information that allows health professionals to make life-saving treatment decisions quickly. This agreement follows closely behind the similar deal made with BD last year.”

Berwyn Clarke, CSO of Lab21, added: “The platform we will be using for the new assay is one which is becoming increasingly well adopted within clinical diagnostic laboratories worldwide. Independent clinical validation studies have already shown that both the new Lab21 Aspergillus and Pneumocystis assays are setting new standards in clinical diagnosis of these clinically important fungal pathogens. We expect the new assays to be significant components of the growing menu of our partner’s molecular diagnostic portfolio.”

Infection caused by Aspergillus is a leading cause of death in immunocompromised patients, with an estimated 10 million people at risk globally each year.

Studies have shown that diagnosis of Aspergillus infection followed by antifungal treatment within the first 10 days of infection reduces mortality from 90 percent to 40 percent - highlighting the need for rapid, accurate testing.

Real-time polymerase chain assays using Lab21 technology have been shown to provide significant advantages in sensitivity and specificity over the current culture techniques.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Lab21 Among First to Offer FDA Approved Companion Diagnostic in the US
CLIA laboratory to provide guidance for the use of Erbitux®.
Monday, July 16, 2012
Lab21 Announces Appointment of Industry Expert Fraser Logue
Dr Logue joins Lab21 team as Group Director of Quality, Regulatory Affairs & Operations Excellence.
Tuesday, February 21, 2012
Scientific News
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Biomedical Imaging at One-Thousandth the Cost
Mathematical modeling enables $100 depth sensor to approximate the measurements of a $100,000 piece of lab equipment.
Improving Outcomes for Lung Cancer and Diabetic Patients
Novel technologies have been developed with support from SBRI Healthcare funding.
New Way of Detecting Cancer
A new RNA test of blood platelets can be used to detect, classify and pinpoint the location of cancer by analysing a sample equivalent to one drop of blood.
Rapid, Portable Ebola Diagnostic
Scientists confirmed the efficiency of the novel Ebola detection method in field trials.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Blood Test Picks Out Prostate Cancer Drug Resistance
Scientists have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug, and identify in advance patients who will not respond to treatment.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Key Piece of MRSA Vaccine Puzzle
New research funded by the Health Research Board and the Wellcome Trust has pinpointed immune cells that could be targeted by an MRSA vaccine.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos